Bavarian Nordic

COPENHAGEN, Denmark, September 20, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the board of directors has appointed Luc Debruyne as an...

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Gerard van Odijk, chairman of the board said: “I am pleased to welcome Luc on the board and look forward to our collaboration until my departure as chairman next year. We are also committed to the development of a next generation COVID-19 vaccine. Luc Debruyne is also highly regarded as an active contributor and advisor in the global health arena with a focus on R&D and access. Luc Debruyne is former President Global Vaccines at GSK, a role he held for the last six years of his 27-year long tenure with the company, where he was a member of GSK’s Corporate Executive Team.